AUTHORS
Larissa Cardoso Zanetti, PhD, Erica Vidal2, Jamile Ramos3, Lays Trajano4, Raquel Amaro5, Ingrid Souza6, Thiago Mitsugi7, Cleyson Barros8, Julia Benincasa9, Oswaldo Okamoto, PhD10, Nelson Hamerschlak Sr, MD PhD11, Lucila Nassif Kerbauy, MD, PhD12
AFFILIATIONS
1 Einstein Hospital Israelita, SAO PAULO, Brazil
2 Einstein Hospital Israelita, SAO PAULO, Brazil
3 Einstein Hospital Israelita, SAO PAULO, Brazil
4 Einstein Hospital Israelita, SAO PAULO, Brazil
5 Einstein Hospital Israelita, SAO PAULO, Brazil
6 Einstein Hospital Israelita, SAO PAULO, Brazil
7 Einstein Hospital Israelita, SAO PAULO, Brazil
8 Einstein Hospital Israelita, SAO PAULO, Brazil
9 Einstein Hospital Israelita, SAO PAULO, Brazil
10 Einstein Hospital Israelita, SAO PAULO, Brazil, Human Genome and Stem Cell Research Center, Department of Genetics and Evolutionary Biology, Biosciences Institute, University of São Paulo (USP), São Paulo, Brazil., Sao Paulo, Brazil
11 Einstein Hospital Israelita, SAO PAULO, Brazil
12 Einstein Hospital Israelita, SAO PAULO, Brazil
ABSTRACT
Introduction: Acute myeloid leukemia (AML) continues to be characterized by poor clinical outcomes and frequent disease relapse, underscoring the urgent need for novel therapeutic strategies. Although chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of several hematologic malignancies, its efficacy in AML has remained limited. Natural killer (NK) cells have emerged as an attractive alternative because of their inherent cytotoxic activity, favorable safety profile, and suitability for off-the-shelf applications. Their scalable manufacturing also has the potential to improve treatment accessibility by reducing production time, infrastructure requirements, and costs, particularly in low- and middle-income countries where access to personalized cell therapies remains limited. Genetic modification with CARs further enhances NK-cell antitumor activity while minimizing the risk of graft-versus-host disease. Among the candidate targets, CD70 has gained considerable attention because of its aberrant and widespread expression in AML and other malignancies.
Methods: Umbilical cord blood–derived NK cells were expanded using irradiated K562 feeder cells expressing membrane-bound IL-21 and 4-1BBL and transduced with a BaEV/TR-pseudotyped lentiviral vector encoding a fourth-generation CD70 CAR containing a CD70-specific scFv, 2B4, CD3ζ, and constitutive IL-15. Cell expansion, viability, CAR expression, vector copy number (VCN), immunophenotype, and IL-15 secretion were evaluated throughout manufacturing. Antigen-specific cytotoxicity, degranulation (CD107a), and cytokine production (IFN-γ and TNF-α) were assessed against CD70⁺ and CD70⁻ target cells. In vivo efficacy was evaluated in NSG mice bearing luciferase-expressing OCI-AML2 leukemia treated with CD70 CAR-NK or untransduced NK cells. Tumor burden, survival, toxicity, CAR-NK persistence and biodistribution, and CD70 expression on residual leukemic cells were assessed.
Results: Efficient lentiviral transduction using a low MOI (0.25) generated CD70 CAR-NK cells with stable CAR expression (~60%), low vector copy number (mean 1.13 copies/cell), robust expansion (~90-fold), and high viability (>95%) (n=3). CAR-NK cells maintained an activated phenotype, characterized by increased expression of activating receptors (NKp44, NKp46, NKG2D, DNAM-1, and CD69) without changes in inhibitory receptor expression (TIGIT, KLRG1, TIM-3, NKB1, and PD-1). Functionally, they displayed potent antigen-specific cytotoxicity against CD70⁺ AML cell lines, achieving >80% target cell lysis at E:T ratio of 5:1, together with significantly enhanced degranulation (CD107a) and IFN-γ/TNF-α production, while showing minimal activity against CD70⁻ targets (n=3). In vivo, CD70 CAR-NK therapy effectively controlled leukemia, reducing bone marrow leukemic burden by 97.4% compared with saline-treated mice (4730.2 vs. 121 leukemic cells per 10⁶ bone marrow cells, p=0.0001) and by 95.2% compared with untransduced NK-treated animals (2499 vs. 121 leukemic cells per 10⁶ bone marrow cells, p=0.0335), consistent with medullary remission. Antitumor activity was associated with robust expansion and persistence of circulating CAR-NK cells, reaching a peak of 7.04 × 10³ NK cells/μL at day 35, together with significant accumulation in the bone marrow and spleen. No circulating leukemic cells were detected in CAR-NK-treated mice, whereas residual disease remained detectable in both control groups. Importantly, CAR-NK treatment was well tolerated, with no evidence of weight loss or clinical toxicity, and significantly prolonged survival. Median survival was not reached by day 55, whereas median survival was 37 and 44 days in the saline and untransduced NK groups, respectively. Notably, 60% of CAR-NK-treated mice remained alive at study completion, while all control animals reached humane endpoints (n=5).
Conclusion: We developed a robust off-the-shelf CD70 CAR-NK platform that combines scalable manufacturing, potent antigen-specific activity, durable in vivo persistence, and an excellent safety profile. In aggressive AML xenograft models, CD70 CAR-NK therapy induced profound bone marrow disease control and significantly prolonged survival without detectable toxicity. Together, these findings support CD70 as a clinically relevant target for CAR-NK therapy and establish this platform as a promising, scalable immunotherapeutic strategy for AML with the potential to improve access to cellular therapies.
DISCLOSURES
Larissa Cardoso Zanetti, PhD: No relevant conflicts of interest to declare.